Trial Profile

A phase 2 clinical trial of ILYX-002 in immune-driven dry eye disease (DED)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ILYX 002 (Primary)
Indications Dry eyes
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

28 Mar 2025 New trial record
12 Mar 2025 According to the Iolyx Therapeutics Media Release, company announced acceptance of abstracts where the company will present new developments and updates on its lead candidate, ILYX-002 from this study, in four upcoming industry events, in Sonoma Eye Meeting, Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, British Contact Lens Association (BCLA) Clinical Conference, and 18th Annual International Ocular and Inflammation Society (IOIS) Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com